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Abstract 
Background: Most data on the clinical epidemiology of atrial fibrillation (AF) are reported 
from Western populations, and data for Asians are limited. We aimed to investigate the 10-
year trends of the prevalence and incidence of non-valvular AF and provide prevalence 
projections till 2060 in Korea. We also investigated the annual risks of adverse outcomes 
among patients with AF. 
Methods: Using the Korean National Health Insurance Service database involving the entire 
Korean population, a total of 679,416 adults with newly diagnosed AF were identified from 
2006 to 2015. The incidence and prevalence of AF and risk of adverse outcomes following 
AF onset were assessed. 
Results: The prevalence of AF progressively increased by 2.10-fold from 0.73% in 2006 to 
1.53% in 2015. The trend of its incidence was flat with a 10-year overall incidence of 1.77 
per 1,000 person-years. The prevalence of AF is expected to reach 5.81% (2,290,591 patients 
with AF) in 2060. For a decade, the risk of all-cause mortality following AF declined by 30% 
(adjusted hazard ratio [HR]: 0.70, 95% confidence interval [CI]: 0.68–0.72), heart failure by 
52% (adjusted HR: 0.48, 95% CI: 0.44–0.51), and ischemic stroke by 9% (adjusted HR: 0.91, 
95% CI: 0.88–0.93). 
Conclusions: The burden of AF among Asian patients is increasing. Although the overall 
risks of cardiovascular events and death following AF onset have decreased over a decade, 
the event rates are still high. Optimized management of any associated comorbidities should 
be part of the holistic management approach for patients with AF. 
 
Keywords: atrial fibrillation; epidemiology; incidence; prevalence; projection; adverse 
outcomes 
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Introduction 
 Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the 
general population.
1, 2
 The prevalence of AF has been projected to increase to 12 million 
individuals in the USA by the year 2050 and 17.9 million in Europe by the year 2060, with 
more than half of these patients aged ≥80 years, leading to a substantial public health and 
economic burden.
3, 4
 The age distribution of AF populations in developed countries is 
expected to shift in the coming years with older age groups becoming more prominent. With 
population aging, AF is likely to become a greater public health burden; thus, reliable 
prevalence and incidence figures are needed for both clinicians and policy-makers.
5
  
AF increases the risk of mortality and morbidity resulting from stroke, congestive 
heart failure, and impaired quality of life, explaining its enormous socioeconomic and 
healthcare implications.
6
 In recent years, important improvements have been made in 
pharmacological and nonpharmacological treatment of associated diseases, such as 
hypertension, myocardial infarction, and heart failure.
7, 8
 However, the current knowledge on 
the incidence, prevalence, and associated cardiovascular morbidity and mortality of AF has 
been predominantly derived from Western countries.
9
 
We investigated the temporal trends of the prevalence and incidence of non-valvular 
AF, projected prevalence of AF to 2060, and risks of cardiovascular events and all-cause 
mortality using the National Health Insurance Service (NHIS) database of the entire Korean 
population from 2006 to 2015. 
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Materials and methods 
This nationwide study was based on the national health claims database established by 
the NHIS of Korea.
10-14
 An insured individual should pay a national health insurance, which is 
proportional to the individual’s income. Although the user charge exists, it is mandatory for all 
Koreans to join the Korean NHIS. The majority (97.1%) of the Korean population is mandatory 
subscribers. The remaining 3% of the population with low income is covered by the Medical Aid 
program. Since 2006, the information of Medical Aid beneficiaries has been incorporated into 
the NHIS database. Therefore, the data extracted from the NHIS database are indeed based on 
the entire Korean population, not causing selection bias. The following medical information is 
provided: patients’ sociodemographic information, their use of inpatient and outpatient services, 
pharmacy dispensing claims, and mortality data. Every population in the NHIS database was 
linked with the Korean social security numbers, and all social security numbers were deleted 
after constructing the cohort by providing serial numbers to prevent leakage of personal 
information. These databases are open to researchers whose study protocols are approved by the 
official review committee. This study was approved by the institutional review board of Yonsei 
University Health System (4-2016-0179). The need for informed consent was waived. 
 
Incidence, prevalence, and projected number of non-valvular AF 
The annual incidence was defined as the rate of acquisition of a new AF diagnosis in the 
health claims data within a 1-year period. To qualify as an incident case, an AF diagnosis must 
have occurred between January 1, 2006 and December 31, 2015 (with the index date being the 
first date of diagnosis within this observation period). AF was diagnosed using the International 
Classification of Disease 10th Revision (ICD-10) codes I48 (AF and atrial flutter), I48.0 (AF), 
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and I48.1 (atrial flutter). We regarded the first date of obtaining the AF-related ICD-10 codes as 
the newly diagnosed year and excluded the first 4 years (2002 to 2005) to avoid the possibility 
for misdiagnosis of preexisting AF for incident AF. Moreover, the patients were considered to 
have AF only when AF was only a discharge diagnosis or confirmed more than twice in the 
outpatient department to ensure diagnostic accuracy. The diagnosis of AF has previously been 
validated in the NHIS database with a positive predictive value (PPV) of 94.1%.
11, 14
 We 
excluded patients aged <20 years and patients with valvular heart disease (with a diagnosis of 
mitral stenosis [ICD-10: I05.0, I05.2, and I34.2] or prosthetic heart valves [ICD-10: Z95.2–Z95.4] 
and insurance claims for valve replacement or valvuloplasty). 
The annual prevalence of AF was calculated by dividing the number of patients with AF 
alive at the end of each year by the number of the total Korean residents alive at the end of that 
year. Supplementary Table I shows the number and distribution of the total Korean residents 
aged ≥20 years. The annual incidence rates of AF in each year were calculated by dividing the 
number of incident cases of AF by the number of person-years at risk among all Korean residents 
of that year who had never been diagnosed with AF. The incidence was presented per 1,000 
person-years. The incidence and prevalence rates were calculated per sex and age group (20–29, 
30–39, 40–49, 50–59, 60–69, 70–79, and ≥80 years). 
The projection of the prevalence of AF was also calculated using a prevalence model as 
previously described.
3, 15
 The details of the prevalence model we used are described in the 
“Projected number of AF” section in the Supplementary Methods. 
 
Definitions of comorbidities and adverse outcomes 
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We obtained information on selected comorbidities from the inpatient and outpatient 
hospital diagnoses (all available primary and secondary diagnoses). Comorbidities were defined 
using the medical claims according to the ICD-10 codes and prescription medication use at the 
time of AF diagnosis. To ensure diagnostic accuracy, the patients were considered to have 
comorbidities (including heart failure, hypertension, diabetes, previous ischemic stroke/transient 
ischemic attack [TIA], previous intracranial bleeding, previous myocardial infarction, peripheral 
arterial disease [PAD], chronic kidney disease [CKD], and malignant neoplasm) when the 
condition was a discharge diagnosis or was confirmed more than twice in an outpatient setting, 
which is similar to the methods of previous studies that used the NHIS data.
10-14
 Economic status 
was categorized into three groups based on the total amount of national health insurance 
premiums paid by the insured individual in each year, which is proportional to the individual’s 
income: low, intermediate, and high economic status. 
We followed up all patients with incidental AF and investigated the epidemiological 
trends of five adverse outcomes, including all-cause mortality, ischemic stroke, intracranial 
bleeding, heart failure admission, and myocardial infarction. The diagnostic accuracies of 
myocardial infarction (PPV: 86.5%), ischemic stroke (PPV: 88–95%), and intracranial bleeding 
(PPV: 78–92%) in the Korean NHIS have been validated previously.13, 16 The definitions of 
comorbidities and adverse outcomes are presented in Supplementary Table II. 
 
Statistical analysis 
Data were presented as means ± standard deviations or medians ± interquartile ranges 
(IQRs) for continuous variables and proportions for categorical variables. The Cochran-Armitage 
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trend test was used for analyzing the temporal trends of categorical variables. The nonparametric 
test for trend by Jonckheere-Terpstra was used for continuous variables. 
We investigated the risks of adverse outcomes in two different manners: (i) We 
calculated the annual risk (%/year) of adverse outcomes among the total patients with prevalent 
AF and non-AF population of Korea by dividing the number of the first lifetime event that 
occurred in each year by the total number of patients at the start of the year who had never 
experienced the event. Since the risks of ischemic stroke, intracranial bleeding, and myocardial 
infarction might be associated with the use of antithrombotic therapies, we analyzed these risks 
among the patients who did not receive antithrombotic therapies within 90 days after enrollment. 
Adverse outcomes among the non-AF Korean population were evaluated using an age- and sex-
matched cohort derived from the Korean NHIS-National Sample Cohort database. The details of 
the non-AF cohort are presented in the “Non-AF cohort from the Korean National Health 
Insurance Service-National Sample Cohort database” section of the Supplementary Methods. (ii) 
We also investigated the association between the calendar years of AF diagnosis and adverse 
outcomes on the 2-year follow-up after AF diagnosis using Cox-proportional hazard regression 
analysis. We estimated the hazard ratios (HRs) of 7 calendar years of AF diagnosis (2007-2013) 
with 2006 as the reference calendar year. The HRs were adjusted for age, sex, economic status, 
and comorbidities at the time of diagnosis, including heart failure, hypertension, diabetes, 
previous ischemic stroke/TIA, previous intracranial bleeding, previous myocardial infarction, 
PAD, CKD, and malignant neoplasm. 
All tests were two-tailed, with P values of <0.05 considered significant. Statistical 
analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA), R version 3.4.1, 
and SPSS version 23.0 (SPSS Inc., Chicago, IL, USA). 
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Results 
Patient characteristics 
During a total of 384,266,047 person-years of follow-up, we identified 679,416 patients 
in the general population with first-time AF diagnosed between 2006 and 2015. The 
characteristics of the patients with newly diagnosed AF in Korea between 2006 and 2015 are 
presented in Table I. The AF diagnoses were almost equally distributed between the men and 
women and stable over time. The proportion of the men increased modestly from 51.7% in 2006 
to 54.2% in 2015 (P value for trend <0.001). The median age of the patients with AF increased 
from 65 (IQR: 53–74) years in 2006 to 71 (IQR: 59–79) years in 2015 (P value for trend <0.001). 
The proportion of the elderlies aged 70–79 and ≥80 years gradually increased from 25.6% and 
12.0% in 2006 to 29.0% and 23.2% in 2015 (both P values for trend <0.001), respectively. The 
proportion of the patients with intermediate and high economic status increased significantly, 
while the proportion of the patients with low economic status decreased from 49.1% in 2006 to 
30.0% in 2015 (all P values for trend <0.001). 
The comorbidity burden increased over time. The most prevalent comorbidities during 
the 10-year period were hypertension (71.1%), heart failure (24.9%), malignant neoplasm 
(23.0%), diabetes (22.7%), and ischemic stroke (19.6%).
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Table I. Characteristics of the patients with newly diagnosed AF in Korea between 2006 and 2015 
 
 
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Overall 
P value 
for trend 
Newly diagnosed AF, n 66,903 66,986 65,829 66,100 67,071 66,743 68,461 69,642 69,961 71,720 679,416  
Age, median (IQR) 
65 
(53–74) 
65 
(53–74) 
66 
(54–75) 
67 
(54–75) 
67 
(55–75) 
68 
(55–76) 
68 
(56–76) 
70 
(58–78) 
70 
(58–78) 
71 
(59–79) 
68 
(56–76) 
<0.001 
20–29 years, % 2.7 2.8 2.5 2.4 2.2 2.0 1.8 1.4 1.5 1.7 2.1 <0.001 
30–39 years, % 5.1 5.2 5.0 4.7 4.5 4.3 3.8 3.3 3.2 3.2 4.2 <0.001 
40–49 years, % 11.2 11.2 10.5 10.2 9.7 8.9 8.4 7.1 7.0 7.0 9.1 <0.001 
50–59 years, % 16.9 17.1 17.1 16.5 16.6 17.1 17.4 16.1 15.8 14.9 16.5 <0.001 
60–69 years, % 26.5 25.6 25.3 24.9 24.1 23.4 22.9 21.0 20.8 21.1 23.5 <0.001 
70–79 years, % 25.6 25.9 26.7 27.4 27.7 28.5 29.1 30.6 30.0 29.0 28.1 <0.001 
≥80 years, % 12.0 12.2 13.0 13.9 15.1 15.8 16.7 20.4 21.8 23.2 16.5 <0.001 
Sex, %             
Male 51.7 52.4 52.3 51.9 52.7 53.3 53.3 54.1 54.1 54.2 53.0 <0.001 
Female 48.3 47.6 47.7 48.1 47.3 46.7 46.7 45.9 45.9 45.8 47.0 <0.001 
Economic status, %             
Low 49.1 44.3 40.5 38.1 41.8 38.8 36.6 30.5 29.7 30.0 37.8 <0.001 
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Intermediate 20.6 38.2 23.9 24.1 23.9 23.9 23.5 24.0 25.0 25.0 25.2 <0.001 
High 30.3 17.5 35.6 37.8 34.3 37.3 40.0 45.5 45.3 45.0 37.0 <0.001 
Comorbidities, %             
Heart failure 22.2 22.8 23.4 23.7 24.0 24.5 25.5 26.5 27.7 28.2 24.9 <0.001 
Hypertension 64.1 66.5 68.4 70.0 71.7 71.8 73.4 75.1 74.9 74.2 71.1 <0.001 
Diabetes 18.5 19.6 20.5 21.6 22.3 22.9 23.8 25.3 26.0 26.2 22.7 <0.001 
Ischemic stroke 14.2 16.0 17.1 19.0 20.2 20.1 21.2 22.6 23.0 22.2 19.6 <0.001 
Intracranial bleeding 1.8 2.0 2.0 2.2 2.6 2.5 2.6 2.7 2.8 2.9 2.4 <0.001 
MI 7.3 7.7 8.2 8.5 8.1 8.0 8.3 8.5 8.8 9.1 8.3 <0.001 
PAD 5.3 6.4 7.8 10.2 11.4 12.1 13.2 14.5 15.0 15.5 11.2 <0.001 
CKD 3.8 4.4 4.8 5.3 5.6 5.9 6.9 7.4 8.1 8.4 6.1 <0.001 
Malignant neoplasm 15.9 17.9 19.6 21.6 22.8 24.2 25.5 25.8 27.2 28.3 23.0 <0.001 
CHA2DS2-VASc score, 
mean (SD) 
2.74 
(1.92) 
2.84 
(2.00) 
2.95 
(2.04) 
3.08 
(2.10) 
3.16 
(2.13) 
3.18 
(2.16) 
3.29 
(2.18) 
3.54 
(2.05) 
3.59 
(2.07) 
3.60 
(2.10) 
3.20 
(2.10) 
<0.001 
HAS-BLED score, 
mean (SD) 
2.07 
(1.38) 
2.19 
(1.43) 
2.30 
(1.45) 
2.42 
(1.47) 
2.50 
(1.48) 
2.54 
(1.49) 
2.62 
(1.50) 
2.72 
(1.50) 
2.75 
(1.52) 
2.75 
(1.54) 
2.49 
(1.59) 
<0.001 
AF, atrial fibrillation; CKD, chronic kidney disease; IQR, interquartile range; MI, myocardial infarction; PAD, peripheral artery disease; SD, 
standard deviation. 
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Prevalence, incidence, and projected number of AF 
Figure 1 shows the temporal trends of the prevalence of AF in Korea. The prevalence 
progressively increased by 2.10-fold from 0.73% in 2006 to 1.53% in 2015 (P value for trend 
<0.001). The prevalence was significantly greater in the men than in the women for all years (P 
<0.001) (Figure 1A). Across all age groups, the prevalence consistently increased over the study 
period, except for the prevalence among those aged 20–29 years, which decreased significantly 
(all P values for trend <0.001) (Figure 1B). The prevalence of AF increased with older age, 
ranging from 0.09% among those aged 20–29 years to 8.15% among those aged ≥80 years in 
2015 (P value for trend <0.001). The annual prevalence of AF between 2006 and 2015 stratified 
by sex and age is presented in Supplementary Table III.  
 
Figure 1. Annual prevalence of AF between 2006 and 2015 stratified according to sex (A) 
and age (B) 
*
P value for increasing trends <0.001. 
†
P value for decreasing trends <0.001. AF, atrial 
fibrillation. 
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Figure 2 shows the incidence of AF from 2006 to 2015. The annual trend of AF incidence 
was almost flat with a 10-year overall incidence of 1.77 per 1,000 person-years. The 10-year 
overall incidence in the men was 1.89 per 1,000 person-years, which was 1.16 times higher than 
1.65 per 1,000 person-years in the women (P <0.001); the tendency was consistent over the study 
period (Figure 2A). The annual AF incidence in the subjects aged ≥80 years significantly 
increased from 12.1 in 2006 to 14.3 per 1,000 person-years in 2015 (P value for trend <0.001), 
while the incidence in all other age groups decreased (all P values for trend <0.001) (Figure 2B 
and Supplementary Table IV). 
 
Figure 2. Annual incidence of AF between 2006 and 2015 stratified according to sex (A) 
and age (B) 
*
P value for increasing trends <0.001. 
†
P value for decreasing trends <0.001. AF, atrial 
fibrillation. 
 
Using the prevalence model previously described and assuming that the incidence of AF 
and mortality remained constant beyond 2015, the projected number of adults with AF will be 
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2,290,538 (prevalence rate: 5.35%) in 2050 and 2,290,591 (prevalence rate: 5.81%) in 2060 
(Figure 3).  
 
Figure 3. Projected prevalence rate (A) and number (B) of AF 
AF, atrial fibrillation. 
 
Trends of the CHA2DS2-VASc and HAS-BLED scores 
The distributions according to the CHA2DS2-VASc and HAS-BLED scores among the 
patients with incident AF are presented in Figure 4. The proportion of the patients with 
CHA2DS2-VASc scores of ≥2 increased from 68.8% to 81.2% from 2006 to 2015 (P value for 
trend <0.001). The proportion of the patients with a high bleeding risk according to the HAS-
BLED score of ≥3 increased from 39.3% in 2006 to 59.1% in 2015 (P value for trend <0.001). 
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Figure 4. Temporal trends of the distribution of the patients with newly diagnosed AF 
according to the CHA2DS2-VASc and HAS-BLED scores between 2006 and 2015 
AF, atrial fibrillation. 
 
Trends of the adverse outcomes among the patients with AF 
The annual trends of the adverse event rates among the patients with prevalent AF and 
non-AF Korean population are presented in Figure 5. Among the patients with prevalent AF, the 
annual event rates for all-cause mortality, ischemic stroke, intracranial bleeding, heart failure 
admission, and myocardial infarction declined for a decade (all P values for trend <0.001). 
However, these did not change significantly among the non-AF Korean population. 
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Figure 5. Temporal trends of the 1-year adverse event rates of the (A) patients with 
prevalent AF and (B) non-AF Korean population in each year 
*
P value for trends <0.001. The 1-year adverse event rates (%/year) were calculated by dividing 
the number of the first lifetime event that occurred in each year by the total number of patients at 
the start of the year who had not experienced that event before. AF, atrial fibrillation; HF, heart 
failure. 
 
The temporal trends of the 2-year risks of adverse outcomes following AF diagnosis are 
presented in Figure 6. The adjusted risk of the patients diagnosed with AF in 2013 for all-cause 
mortality declined by 30% (adjusted HR: 0.70, 95% confidence interval [CI]: 0.68–0.72), heart 
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failure by 52% (adjusted HR: 0.48, 95% CI: 0.44–0.51), myocardial infarction by 59% (adjusted 
HR: 0.41, 95% CI: 0.39–0.43), ischemic stroke by 9% (adjusted HR: 0.91, 95% CI: 0.88–0.93), 
and intracranial bleeding by 26% (adjusted HR: 0.74, 95% CI: 0.70–0.79), compared with those 
of the patients diagnosed in 2006 (Figure 6 and Supplementary Table V). 
Figure 6. Temporal trends of the adjusted HRs of the adverse outcomes in the 2-year 
follow-up after AF diagnosis 
The HR was adjusted for age, sex, economic status, and comorbidities. AF, atrial fibrillation; HF, 
heart failure; HR, hazard ratio.  
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Discussion 
To the best of our knowledge, the current study used the largest nationwide cohort 
consisting of the entire Korean population to estimate the current and future non-valvular AF 
incidence and prevalence. Our principal findings are as follows: (i) The prevalence of AF 
progressively increased by 2.10-fold from 0.73% in 2006 to 1.53% in 2015; (ii) the trend of 
annual AF incidence was flat with a 10-year overall incidence of 1.77 per 1,000 person-years; (iii) 
the prevalence of AF was estimated to be 5.81% in 2060; and (iv) the risks of all-cause mortality, 
ischemic stroke, intracranial bleeding, heart failure, and myocardial infarction following onset of 
AF decreased markedly over a decade. 
 
Prevalence, incidence, and projected number of AF 
Over the course of 10 years of observation, we observed an increasing prevalence and a 
flat incidence of AF. The increase in the prevalence is in line with the findings for most Western 
populations.
4, 17-19
 Across all age groups and both sexes, the prevalence consistently increased 
over the study period with higher absolute numbers in the older patients and men. The 
prevalence of AF in Korea was similar to the recently reported AF prevalence rates from 1.1% to 
1.6% in other Asian countries (1.07% in Taiwan,
17
 1.5% in Singapore,
20
 and 1.6% in Japan
21
). 
The prevalence of AF is generally lower in Asia than in Western countries (i.e., Caucasians).
22, 23
 
Although the precise mechanisms behind the differences in AF epidemiology between Asians 
and Caucasians remain unclear, part of the global variation may be attributable to the better 
surveillance in developed countries, and the prevalence of AF in some Asian countries is 
probably underestimated.
22, 24
 Furthermore, the longer life expectancy and more prevalent 
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cardiovascular risk factors and diseases, including smoking, obesity, hypertension, ischemic 
heart diseases, and diabetes, in developed Western countries may play important roles.
24
  
Most prior data on AF incidence rates were reported from studies performed in Europe 
and North America. The reported AF incidence rate ranges from 3.3 to 9.9 per 1,000 person-
years among studies conducted in Europe
23, 25, 26
 and from 3.3 to 19.2 per 1,000 person-years 
among predominantly USA-based cohort studies.
3, 19, 27
 The 10-year overall incidence of AF in 
the present study was 1.77 per 1,000 person-years, which is lower than that in Europe and the 
USA. However, our AF incidence rate is comparable to those described in a Taiwanese 
nationwide cohort study (i.e., 1.51 per 1,000 person-years).
17
 Consistent with our findings, the 
annual trend of AF incidence was stable in Taiwan. 
Similar to the growing burden of AF worldwide,
22
 the AF prevalence and the absolute 
number of patients with AF would continuously increase over the coming decades in Korea 
based on our projected estimations. Indeed, the AF prevalence in Korea was estimated to be 5.35% 
in 2050, which is higher than the projected AF prevalence of 4.01% in Taiwan.
17
 
 
Risks of adverse outcomes 
Over the last 5 decades, the AF-associated mortality decreased by 25% in the 
Framingham heart study.
19
 In Korea, we observed a 20% reduction in the mortality rate over a 
decade from 5.0% per year in 2006 to 4.0% per year in 2015. The improved survival after AF 
onset may arise from (1) earlier detection (lead time) owing to heightened awareness, (2) 
changed diagnostic criteria (as described above), (3) enhanced surveillance of patients with AF, 
(4) advances in the guideline-recommended treatments for AF, including oral anticoagulation to 
reduce risks of embolization, and (5) more aggressive treatment of complications and 
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comorbidities, such as hypertension, ischemic heart disease, heart failure, and 
hypercholesterolemia.
18
 
Given the high mortality associated with heart failure and stroke,
28, 29
 the 52% reduction 
in heart failure subsequent to AF observed over the study period and the 9% reduction in the risk 
of ischemic stroke were likely to have contributed substantially to the improved survival. 
Although our results showing a declining associated risk for heart failure and stroke following 
AF are in line with those for other Western populations,
18
 the 1-year rates of heart failure and 
stroke were 0.2% and 1.8% per year, respectively, which are still higher than 0.1% and 0.6% per 
year of the age- and sex-matched non-AF population in 2013. 
 
Limitations 
The present study has several limitations given the nature of the nationwide registry 
dataset we used. Such studies using administrative databases might be susceptible to errors from 
coding inaccuracies. To minimize this problem, we examined the nationwide cohort and applied 
the definition already validated in previous studies that used the Korean NHIS sample cohort.
11, 
13, 14, 16
 Since we defined AF cases only with ICD-10 codes, it is possible that either paroxysmal 
or asymptomatic AF cases, which were not ascertained by these codes, were not recorded. Also, 
we could not analyse paroxysmal, persistent, and permanent AF subgroups separately. Patients 
younger than 20 years were excluded from the study population. This approach can omit some 
patients with AF. However, the prevalence among children and adolescents could be 
underestimated owing to the lack of symptoms, fewer visits to medical institutions, and lack of 
routine ECG check-up. Therefore, most previous studies have included only adult populations.
17-
21, 23
 Although it would be relevant to stratify all adverse outcomes according to antithrombotic 
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therapies, we provided the risks of ischemic stroke, intracranial bleeding, and myocardial 
infarction, which could be altered by antithrombotic therapies, only among the patients who did 
not receive antithrombotic therapies. By investigating the risk of first lifetime events which were 
not affected by antithrombotic therapies, we attempted to understand the disease course after 
new-onset AF more clearly. Despite these limitations, this study evaluated longitudinal data from 
the entire Korean adult population. Therefore, our findings may reflect the “real-world” AF 
burden on a nationwide scale.  
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Conclusion 
The burden of AF among Asian patients is increasing. Although the overall risks of death, 
ischemic stroke, intracranial bleeding, heart failure, and myocardial infarction following onset of 
AF have decreased over a decade, the absolute event rates are still high. Optimized management 
of any associated comorbidities should be part of the holistic management approach for patients 
with AF. 
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